INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1001, 3846, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1002, 3847, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1003, 8157, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1004, 8158, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1005, 22734, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1006, 30918, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1007, 30919, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1008, 3846, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1009, 3847, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1010, 8157, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1011, 8158, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1012, 22734, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1013, 30918, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1014, 30919, 'Midazolam', 'The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.', 'alcohol', 'Moderate', 'The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1015, 0, 'Midostaurin', 'Grapefruit juice may significantly increase the plasma concentrations of midostaurin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.', 'grapefruit juice', 'Major', 'The manufacturer recommends taking midostaurin with food.  Midostaurin was administered with food in clinical trials.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with midostaurin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1016, 0, 'Mifepristone', 'Food may significantly increase the plasma concentrations of mifepristone.', 'grapefruit juice', 'Moderate', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, it should be taken with food to achieve consistent plasma drug levels.  Patients should be advised to avoid consuming grapefruit or grapefruit juice during treatment with mifepristone, as it may cause increased adverse effects such as headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia, adrenal insufficiency, vaginal bleeding, arthralgia, peripheral edema, and hypertension.  Because mifepristone is eliminated slowly from the body, the interaction with grapefruit juice may be observed for a prolonged period.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1017, 0, 'Mipomersen', 'Coadministration with alcohol may increase the risk of hepatotoxicity associated with the use of mipomersen.', 'alcohol', 'Major', 'Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1018, 2385, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1019, 6240, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1020, 15165, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1021, 15166, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1022, 15358, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1023, 22818, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1024, 22820, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1025, 22821, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1026, 30201, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1027, 30553, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1028, 32460, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1029, 33813, 'Mirabegron', 'Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.', 'high-fat foods', 'Minor', 'In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1030, 229, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1031, 5890, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1032, 7509, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1033, 8215, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1034, 11343, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1035, 13593, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1036, 15379, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1037, 15412, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1038, 19585, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1039, 20186, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1040, 20187, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1041, 20196, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1042, 20197, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1043, 20210, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1044, 20216, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1045, 22799, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1046, 22801, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1047, 22802, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1048, 22803, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1049, 23414, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1050, 24398, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1051, 24743, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1052, 24745, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1053, 25791, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1054, 25792, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1055, 25811, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1056, 25812, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1057, 26586, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1058, 33210, 'Minoxidil', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1059, 21947, 'Miglitol', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1060, 21948, 'Miglitol', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1061, 8238, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1062, 9826, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1063, 13087, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1064, 14323, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1065, 22839, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1066, 22841, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1067, 25853, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1068, 29838, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1069, 33212, 'Mirtazapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1070, 0, 'Miltefosine', 'Administration of miltefosine with food may help reduce gastrointestinal adverse effects such as nausea, vomiting, abdominal pain, and diarrhea.', 'food', 'Moderate', 'Miltefosine should be administered with meals to help improve gastrointestinal tolerance.  Patients should be advised to contact their physician if they develop severe or persistent vomiting or diarrhea, and to drink plenty of fluids to help prevent dehydration and kidney injury.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1071, 0, 'Migalastat', 'Food may reduce the oral bioavailability of migalastat.  When migalastat was administered one hour before a high-fat (850 calories; 56% from fat) or light meal (507 calories; 30% from fat), or one hour after a light meal, mean migalastat peak plasma concentration (Cmax) decreased by 15% to 39% and systemic exposure (AUC) decreased by 37% to 42% compared to administration in the fasting state.', 'high-fat foods', 'Moderate', 'Migalastat should be taken on an empty stomach.  Patients should avoid eating for at least 2 hours before and 2 hours after taking migalastat to give a minimum 4 hours fast.  Clear liquids can be consumed during this 4-hour period.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1072, 6693, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1073, 14737, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1074, 22757, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1075, 22758, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1076, 22759, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1077, 22760, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1078, 22761, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1079, 22762, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1080, 23184, 'Milnacipran', 'Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.', 'alcohol', 'Moderate', 'Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1081, 15465, 'Modafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.', 'dairy products', 'Minor', 'Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1082, 22882, 'Modafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.', 'dairy products', 'Minor', 'Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1083, 22887, 'Modafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.', 'dairy products', 'Minor', 'Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1084, 0, 'Molindone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1085, 22796, 'Moexipril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1086, 25252, 'Moexipril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1087, 25253, 'Moexipril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1088, 22796, 'Moexipril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1089, 25252, 'Moexipril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1090, 25253, 'Moexipril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1091, 8332, 'Morphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1092, 22989, 'Morphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1093, 23054, 'Morphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1094, 10102, 'Asenapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1095, 14459, 'Asenapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1096, 14460, 'Asenapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1097, 14462, 'Asenapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1098, 24196, 'Mycophenolic acid', 'Administration of enteric coated mycophenolic acid with meals may alter its pharmacokinetics relative to administration in the fasting state.  When mycophenolic acid 720 mg was administered with a high-fat meal, there was a 33% decrease in the peak plasma concentration (Cmax); a 3.5-hour increase in delay time for the rise of plasma mycophenolic acid; and a 5-hour delay in the time to reach peak plasma concentration (Tmax).  However, no effect was observed on the systemic exposure of mycophenolic acid.', 'high-fat foods', 'Moderate', 'To avoid variability in drug absorption between doses, enteric coated formulations of mycophenolic acid should be taken on an empty stomach, one hour before or two hours after food intake.  The tablets should be swallowed whole and not crushed, chewed or divided in order to maintain the integrity of the enteric coating.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1099, 0, 'Nafcillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1100, 0, 'Nabilone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1101, 0, 'Nadolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1102, 0, 'Nadolol', 'Coadministration with green tea may significantly decrease the plasma concentrations of nadolol.  The mechanism of interaction has not been established, but may involve inhibition of OATP1A2-mediated uptake of nadolol in the intestine by catechins in green tea.', 'green tea', 'Moderate', 'Based on available data, patients should be advised to limit their consumption of green tea and green tea extracts during treatment with nadolol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1103, 17536, 'Nateglinide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1104, 27465, 'Nateglinide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1105, 27466, 'Nateglinide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1106, 721, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1107, 3401, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1108, 6738, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1109, 6993, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1110, 17233, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1111, 25953, 'Naltrexone', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1112, 21415, 'Asparaginase Erwinia chrysanthemi', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury.  Asparaginase-associated hepatotoxicity has been reported more commonly in adults than in children and has been strongly associated with obesity.  Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults.  Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'alcohol', 'Moderate', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins).  Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs.  Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1113, 0, 'Naldemedine', 'Grapefruit juice may increase the plasma concentrations of naldemedine.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Naldemedine may be taken with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with naldemedine.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1114, 244, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1115, 8548, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1116, 9085, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1117, 23220, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1118, 23221, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1119, 23223, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1120, 23227, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1121, 23228, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1122, 23229, 'Nalbuphine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1123, 0, 'Naloxegol', 'Grapefruit juice may significantly increase the plasma concentrations of naloxegol.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with naloxegol should avoid consumption of grapefruit and grapefruit juice.  Naloxegol should be taken on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1124, 4596, 'Nabumetone', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1125, 4597, 'Nabumetone', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1126, 23206, 'Nabumetone', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1127, 23207, 'Nabumetone', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1128, 23208, 'Nabumetone', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1129, 296, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1130, 8543, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1131, 8577, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1132, 23200, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1133, 23222, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1134, 23259, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1135, 23260, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1136, 23261, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1137, 23262, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1138, 24265, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1139, 27732, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1140, 33251, 'Naproxen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1141, 8625, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1142, 8781, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1143, 8782, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1144, 22370, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1145, 22888, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1146, 23332, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1147, 23337, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1148, 23340, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1149, 23341, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1150, 23342, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1151, 23411, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1152, 23510, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1153, 23672, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1154, 27798, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1155, 32219, 'Nebivolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1156, 0, 'Nefazodone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1157, 0, 'Neratinib', 'Grapefruit, grapefruit juice, grapefruit hybrids, pomelos, star-fruit, and Seville oranges may increase the plasma concentrations of neratinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'The manufacturer recommends administering neratinib with food at approximately the same time every day.  Patients should avoid consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomelos, star-fruit, and Seville oranges during treatment with neratinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1158, 28190, 'Niacin', 'Ethanol can exacerbate the cutaneous flushing that is a common side effect of niacin.  At least one case of delirium and lactic acidosis has been reported with coadministration of these drugs, although data are limited.  ', 'alcohol', 'Moderate', 'Coadministration should probably be discouraged, particularly since chronic consumption of large amounts of alcohol is associated with hyperlipidemia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1159, 24646, 'Nicardipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1160, 24646, 'Nicardipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1161, 27924, 'Nilotinib', 'Grapefruit juice may increase the plasma concentrations of nilotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1162, 27925, 'Nilotinib', 'Grapefruit juice may increase the plasma concentrations of nilotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1163, 23973, 'Nintedanib', 'Food enhances the oral bioavailability of nintedanib.  After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions.  Absorption was also delayed, as indicated by an increase in the median time to reach maximum plasma concentration (Tmax) from 2 hours in the fasted state to approximately 4 hours under fed conditions, irrespective of the type of food ingested.', 'food', 'Moderate', 'Nintedanib should be administered with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1164, 23974, 'Nintedanib', 'Food enhances the oral bioavailability of nintedanib.  After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions.  Absorption was also delayed, as indicated by an increase in the median time to reach maximum plasma concentration (Tmax) from 2 hours in the fasted state to approximately 4 hours under fed conditions, irrespective of the type of food ingested.', 'food', 'Moderate', 'Nintedanib should be administered with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1165, 1064, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1166, 1067, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1167, 1068, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1168, 1071, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1169, 1073, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1170, 1631, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1171, 1632, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1172, 11268, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1173, 11270, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1174, 14004, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1175, 14005, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1176, 14525, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1177, 15164, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1178, 27762, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1179, 28023, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1180, 28025, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1181, 28026, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1182, 28033, 'Atenolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1183, 1064, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1184, 1067, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1185, 1068, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1186, 1071, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1187, 1073, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1188, 1631, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1189, 1632, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1190, 11268, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1191, 11270, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1192, 14004, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1193, 14005, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1194, 14525, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1195, 15164, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1196, 27762, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1197, 28023, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1198, 28025, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1199, 28026, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1200, 28033, 'Atenolol', 'Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.', 'orange juice', 'Moderate', 'Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1201, 14100, 'Nilutamide', 'Alcohol intolerance has been reported in 5% to 20% of patients following administration of nilutamide in clinical studies.  Symptoms include facial flushes, malaise, and hypotension.', 'alcohol', 'Moderate', 'Consumption of alcoholic beverages should be avoided in patients who experience alcohol intolerance with nilutamide.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1202, 0, 'Nisoldipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1203, 0, 'Nisoldipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1204, 8878, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1205, 8879, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1206, 15461, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1207, 19509, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1208, 23604, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1209, 23605, 'Nimodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1210, 8878, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1211, 8879, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1212, 15461, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1213, 19509, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1214, 23604, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1215, 23605, 'Nimodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1216, 793, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1217, 4037, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1218, 8553, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1219, 8554, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1220, 8884, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1221, 8885, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1222, 9642, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1223, 14235, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1224, 16922, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1225, 16923, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1226, 16924, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1227, 16925, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1228, 16926, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1229, 18121, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1230, 23617, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1231, 23620, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1232, 23621, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1233, 23622, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1234, 25435, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1235, 28592, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1236, 28593, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1237, 28594, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1238, 28743, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1239, 28744, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1240, 29746, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1241, 30010, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1242, 30011, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1243, 33900, 'Nitazoxanide', 'Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.', 'food', 'Moderate', 'Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1244, 3424, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1245, 3425, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1246, 7728, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1247, 8496, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1248, 8898, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1249, 8902, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1250, 15842, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1251, 16810, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1252, 19975, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1253, 19976, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1254, 23628, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1255, 23629, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1256, 23630, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1257, 23631, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1258, 23635, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1259, 23637, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1260, 23639, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1261, 0, 'Nitisinone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1262, 4278, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1263, 4279, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1264, 13459, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1265, 23577, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1266, 23578, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1267, 4278, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1268, 4279, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1269, 13459, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1270, 23577, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1271, 23578, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1272, 0, 'Nifurtimox', 'Use of alcohol or products containing alcohol during therapy with nitrofurans may result in a disulfiram-like reaction in some patients.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by nitrofurans in a manner similar to disulfiram.', 'alcohol', 'Major', 'Consumption of alcohol is considered contraindicated during nifurtimox therapy.  To ensure maximal oral absorption, nifurtimox should be administered with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1273, 23613, 'Nitroprusside', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1274, 23627, 'Nitroprusside', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1275, 0, 'Atazanavir', 'Administration of atazanavir with food enhances oral bioavailability and reduces pharmacokinetic variability.The coefficient of variation of AUC and Cmax decreased by approximately one-half when given with either a light or high-fat meal compared to the fasting state.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, atazanavir should be administered with or immediately after a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1276, 4285, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1277, 8666, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1278, 8969, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1279, 8970, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1280, 9312, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1281, 23701, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1282, 23722, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1283, 4285, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1284, 8666, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1285, 8969, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1286, 8970, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1287, 9312, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1288, 23701, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1289, 23722, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', 'Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1290, 0, 'Nortriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1291, 2569, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1292, 8983, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1293, 16315, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1294, 25248, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1295, 27513, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1296, 2569, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1297, 8983, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1298, 16315, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1299, 25248, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1300, 27513, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1301, 10188, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1302, 12372, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1303, 15062, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1304, 15063, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1305, 26499, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1306, 2736, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1307, 2985, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1308, 9201, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1309, 9202, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1310, 9270, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1311, 16732, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1312, 16733, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1313, 24031, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1314, 24032, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1315, 24033, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1316, 24137, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1317, 24606, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1318, 24607, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1319, 31082, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1320, 741, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1321, 744, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1322, 4331, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1323, 14174, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1324, 18498, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1325, 18500, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1326, 21783, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1327, 21784, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1328, 23726, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1329, 23727, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1330, 24018, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1331, 24019, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1332, 24021, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1333, 24022, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1334, 24023, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1335, 29054, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1336, 31021, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1337, 741, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1338, 744, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1339, 4331, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1340, 14174, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1341, 18498, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1342, 18500, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1343, 21783, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1344, 21784, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1345, 23726, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1346, 23727, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1347, 24018, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1348, 24019, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1349, 24021, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1350, 24022, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1351, 24023, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1352, 29054, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1353, 31021, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1354, 0, 'Atovaquone', 'Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day.  Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1355, 0, 'Atovaquone', 'Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone.', 'dairy products', 'Moderate', 'To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day.  Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1356, 1088, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1357, 1089, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1358, 1090, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1359, 1094, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1360, 1095, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1361, 1097, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1362, 1678, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1363, 4008, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1364, 4009, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1365, 4735, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1366, 7349, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1367, 7350, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1368, 7352, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1369, 7355, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1370, 7359, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1371, 7372, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1372, 7397, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1373, 7398, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1374, 7399, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1375, 11556, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1376, 13234, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1377, 13512, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1378, 14227, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1379, 14228, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1380, 14563, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1381, 14570, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1382, 15442, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1383, 16266, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1384, 18869, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1385, 21870, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1386, 21882, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1387, 21884, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1388, 21885, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1389, 21887, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1390, 21889, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1391, 21890, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1392, 21891, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1393, 21893, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1394, 21894, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1395, 21905, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1396, 21906, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1397, 21907, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1398, 21915, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1399, 21916, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1400, 21935, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1401, 21936, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1402, 24268, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1403, 26314, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1404, 26558, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1405, 26559, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1406, 26940, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1407, 26941, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1408, 28349, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1409, 28350, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1410, 29588, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1411, 30215, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1412, 30833, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1413, 30834, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1414, 31823, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1415, 1088, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1416, 1089, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1417, 1090, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1418, 1094, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1419, 1095, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1420, 1097, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1421, 1678, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1422, 4008, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1423, 4009, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1424, 4735, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1425, 7349, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1426, 7350, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1427, 7352, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1428, 7355, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1429, 7359, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1430, 7372, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1431, 7397, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1432, 7398, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1433, 7399, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1434, 11556, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1435, 13234, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1436, 13512, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1437, 14227, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1438, 14228, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1439, 14563, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1440, 14570, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1441, 15442, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1442, 16266, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1443, 18869, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1444, 21870, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1445, 21882, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1446, 21884, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1447, 21885, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1448, 21887, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1449, 21889, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1450, 21890, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1451, 21891, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1452, 21893, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1453, 21894, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1454, 21905, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1455, 21906, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1456, 21907, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1457, 21915, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1458, 21916, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1459, 21935, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1460, 21936, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1461, 24268, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1462, 26314, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1463, 26558, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1464, 26559, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1465, 26940, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1466, 26941, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1467, 28349, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1468, 28350, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1469, 29588, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1470, 30215, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1471, 30833, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1472, 30834, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1473, 31823, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1474, 0, 'Oliceridine', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oliceridine.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oliceridine.  Any history of alcohol or illicit drug use should be considered when prescribing oliceridine, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oliceridine should preferably avoid the consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1475, 52, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1476, 3412, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1477, 4370, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1478, 7103, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1479, 9189, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1480, 10592, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1481, 12958, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1482, 12959, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1483, 12960, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1484, 13619, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1485, 14176, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1486, 15293, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1487, 16782, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1488, 18830, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1489, 19774, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1490, 19808, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1491, 20891, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1492, 20892, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1493, 21605, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1494, 23998, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1495, 23999, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1496, 24000, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1497, 24002, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1498, 25222, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1499, 26604, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1500, 26605, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1501, 26606, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1502, 30056, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1503, 30057, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1504, 30059, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1505, 30190, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1506, 30191, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1507, 32234, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1508, 32301, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1509, 32302, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1510, 0, 'Omadacycline', 'Administration with food, particularly dairy products, may reduce the absorption of omadacycline.  The calcium content of these foods may form nonabsorbable chelates with omadacycline.', 'dairy products', 'Moderate', 'Omadacycline should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1511, 22141, 'Olaparib', 'Grapefruit juice may significantly increase the plasma concentrations of olaparib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1512, 22142, 'Olaparib', 'Grapefruit juice may significantly increase the plasma concentrations of olaparib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1513, 0, 'Opicapone', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1514, 0, 'Opicapone', 'Food may reduce the rate and extent of absorption of opicapone.  When opicapone was administered following a moderate fat/moderate calorie meal, mean opicapone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 62% and 31%, respectively, while the time to reach peak concentration (Tmax) was delayed by 4 hours.', 'high-fat foods', 'Moderate', 'Patients should avoid eating 1 to 2 hours before and after taking opicapone.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1515, 1116, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1516, 1117, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1517, 11376, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1518, 12144, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1519, 20934, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1520, 20935, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1521, 30164, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1522, 30165, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1523, 8977, 'Orphenadrine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1524, 23709, 'Orphenadrine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1525, 0, 'Ospemifene', 'Food significantly enhances the oral bioavailability of ospemifene.  In a cross-study comparison, administration of a single 60 mg dose of ospemifene with a high-fat/high-calorie meal (860 kcal) in postmenopausal women increased ospemifene peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.3- and 1.7-fold, respectively, compared to administration under fasted condition.', 'high-fat foods', 'Moderate', 'Ospemifene should be taken once daily with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1526, 521, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1527, 522, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1528, 609, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1529, 610, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1530, 611, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1531, 612, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1532, 4968, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1533, 4985, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1534, 4986, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1535, 4988, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1536, 4989, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1537, 5008, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1538, 5012, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1539, 5014, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1540, 5015, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1541, 6085, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1542, 13988, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1543, 13990, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1544, 13991, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1545, 13992, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1546, 16673, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1547, 16939, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1548, 16940, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1549, 18789, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1550, 19197, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1551, 19218, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1552, 19222, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1553, 19225, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1554, 20036, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1555, 24655, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1556, 24385, 'Oxaprozin', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1557, 24386, 'Oxaprozin', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1558, 1109, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1559, 1110, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1560, 1111, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1561, 6629, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1562, 14591, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1563, 14592, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1564, 9475, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1565, 9476, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1566, 11669, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1567, 11672, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1568, 14143, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1569, 14144, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1570, 24370, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1571, 24387, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1572, 24388, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1573, 24400, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1574, 26920, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1575, 26921, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1576, 26922, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1577, 28508, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1578, 28511, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1579, 9483, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1580, 16680, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1581, 16681, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1582, 24395, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1583, 0, 'Oxymorphone', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1584, 0, 'Ozanimod', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with ozanimod.  The mechanism is inhibition of monoamine oxidase type A (MAO-A) by metabolites of ozanimod.  MAO-A is the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with ozanimod should avoid consumption of products that contain large amounts of amines (e.g., tyramine) and protein foods in which ageing or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of ozanimod therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1585, 8130, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1586, 20677, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1587, 20678, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1588, 20679, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1589, 8130, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1590, 20677, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1591, 20678, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1592, 20679, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1593, 151, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1594, 11330, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1595, 11336, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1596, 11338, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1597, 11339, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1598, 11340, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1599, 27721, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1600, 28086, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1601, 28087, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1602, 28088, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1603, 4454, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1604, 4455, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1605, 4457, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1606, 5419, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1607, 6347, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1608, 6352, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1609, 6353, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1610, 9544, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1611, 9545, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1612, 9554, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1613, 11212, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1614, 14273, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1615, 14274, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1616, 14275, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1617, 19674, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1618, 20879, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1619, 20880, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1620, 20881, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1621, 20882, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1622, 24438, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1623, 24440, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1624, 24441, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1625, 24442, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1626, 24443, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1627, 24445, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1628, 24446, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1629, 24447, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1630, 24448, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1631, 24460, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1632, 24461, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1633, 27945, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1634, 28761, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1635, 28762, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1636, 28763, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1637, 28764, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1638, 33367, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1639, 33368, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1640, 33369, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1641, 4454, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1642, 4455, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1643, 4457, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1644, 5419, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1645, 6347, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1646, 6352, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1647, 6353, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1648, 9544, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1649, 9545, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1650, 9554, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1651, 11212, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1652, 14273, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1653, 14274, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1654, 14275, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1655, 19674, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1656, 20879, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1657, 20880, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1658, 20881, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1659, 20882, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1660, 24438, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1661, 24440, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1662, 24441, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1663, 24442, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1664, 24443, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1665, 24445, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1666, 24446, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1667, 24447, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1668, 24448, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1669, 24460, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1670, 24461, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1671, 27945, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1672, 28761, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1673, 28762, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1674, 28763, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1675, 28764, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1676, 33367, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1677, 33368, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1678, 33369, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1679, 2994, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1680, 3521, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1681, 3522, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1682, 3762, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1683, 11969, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1684, 11970, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1685, 17403, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1686, 17404, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1687, 17916, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1688, 17918, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1689, 17919, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1690, 18577, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1691, 24407, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1692, 24408, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1693, 24409, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1694, 28854, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1695, 31540, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1696, 6545, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1697, 20914, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1698, 20916, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1699, 20917, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1700, 20918, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1701, 24464, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1702, 24465, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1703, 24747, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1704, 28443, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1705, 28444, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1706, 28445, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1707, 28446, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1708, 24417, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1709, 24418, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1710, 24419, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1711, 24420, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1712, 0, 'Panobinostat', 'Grapefruit juice may increase the plasma concentrations of panobinostat.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients should avoid consumption of grapefruit or grapefruit juice during treatment with panobinostat.  The manufacturer also recommends avoiding star fruit, Seville oranges, pomegranate, and pomegranate juice.  Panobinostat may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1713, 9657, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1714, 9669, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1715, 10366, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1716, 10367, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1717, 17265, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1718, 24597, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1719, 24598, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1720, 24601, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1721, 24602, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1722, 24603, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1723, 33383, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1724, 33384, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1725, 33385, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1726, 0, 'Pegaspargase', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury.  Asparaginase-associated hepatotoxicity has been reported more commonly in adults than in children and has been strongly associated with obesity.  Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults.  Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.  ', 'alcohol', 'Moderate', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins).  Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs.  Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1727, 0, 'Patiromer', 'Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness', 'food', 'Moderate', 'Patiromer should be administered with food at least 3 hours before or 3 hours after other oral medications.  Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible.  Otherwise, clinical response and/or blood levels should be monitored where possible.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1728, 0, 'Acetaminophen', 'Chronic, excessive consumption of alcohol may increase the risk of acetaminophen-induced hepatotoxicity, which has included rare cases of fatal hepatitis and frank hepatic failure requiring liver transplantation.  The proposed mechanism is induction of hepatic microsomal enzymes during chronic alcohol use, which may result in accelerated metabolism of acetaminophen and increased production of potentially hepatotoxic metabolites.', 'alcohol', 'Major', 'In general, chronic alcoholics should avoid regular or excessive use of acetaminophen.  Alternative analgesic/antipyretic therapy may be appropriate in patients who consume three or more alcoholic drinks per day.  However, if acetaminophen is used, these patients should be cautioned not to exceed the recommended dosage (maximum 4 g/day in adults and children 12 years of age or older).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1729, 14520, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1730, 14521, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1731, 14522, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1732, 14655, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1733, 14656, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1734, 14657, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1735, 18005, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1736, 18518, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1737, 18523, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1738, 18524, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1739, 18525, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1740, 0, 'Penbutolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1741, 0, 'Pemigatinib', 'Grapefruit juice may increase the plasma concentrations of pemigatinib, which is primarily metabolized by CYP450 3A4 in vitro.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'Pemigatinib may be administered with or without food.  Patients should avoid consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit extract during treatment with pemigatinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1742, 14775, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1743, 25748, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1744, 25749, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1745, 25750, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1746, 0, 'Pentazocine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1747, 0, 'Pentazocine', 'Smoking tobacco may decrease the plasma concentrations and effects of pentazocine by enhancing its metabolic clearance.', 'cigarette', 'Moderate', 'The possibility of reduced therapeutic effects of pentazocine should be considered in smokers.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1748, 16931, 'Penicillamine', 'Food may interfere with the gastrointestinal absorption of penicillamine.', 'food', 'Moderate', 'Penicillamine should be administered on an empty stomach, at least one hour before or two hours after meals, and at least one hour apart from any other drug, food, or milk.  This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1749, 25939, 'Penicillamine', 'Food may interfere with the gastrointestinal absorption of penicillamine.', 'food', 'Moderate', 'Penicillamine should be administered on an empty stomach, at least one hour before or two hours after meals, and at least one hour apart from any other drug, food, or milk.  This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1750, 0, 'Perampanel', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1751, 0, 'Pentobarbital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1752, 0, 'Pergolide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1753, 0, 'Avatrombopag', 'Food reduces the variability in oral absorption and bioavailability of avatrombopag.  According to the product labeling, avatrombopag peak plasma concentration (Cmax) and systemic exposure (AUC) were not affected when administered with either a low-fat (500 calories; 3 g fat, 15 g proteins, 108 g carbohydrates) or high-fat (918 calories; 59 g fat, 39 g proteins, 59 g carbohydrates) meal.  However, the variability of avatrombopag exposure was reduced by 40% to 60% with food, and the time to reach Cmax was delayed by 0 to 2 hours relative to the fasted state.', 'high-fat foods', 'Moderate', 'To ensure consistent absorption and plasma drug levels, avatrombopag should be taken with food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1754, 11667, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1755, 28506, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1756, 28507, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1757, 29604, 'Pazopanib', 'Grapefruit juice may increase the plasma concentrations of pazopanib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Pazopanib should be administered at least one hour before or two hours after a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1758, 29605, 'Pazopanib', 'Grapefruit juice may increase the plasma concentrations of pazopanib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Pazopanib should be administered at least one hour before or two hours after a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1759, 206, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1760, 3125, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1761, 8994, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1762, 16875, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1763, 16876, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1764, 16877, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1765, 25414, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1766, 206, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1767, 3125, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1768, 8994, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1769, 16875, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1770, 16876, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1771, 16877, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1772, 25414, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1773, 0, 'Avapritinib', 'Grapefruit juice may increase the plasma concentrations of avapritinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'Avapritinib should be administered on an empty stomach at least 1 hour before or 2 hours after a meal.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with avapritinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1774, 0, 'Pexidartinib', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib.  Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury.', 'alcohol', 'Major', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.  Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter.  Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity.  A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib.  Liver function tests should be performed weekly for the first month after rechallenge.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1775, 0, 'Pexidartinib', 'The presence of food may increase the absorption and toxicity of pexidartinib.  Administration of pexidartinib with a high-fat meal increased peak plasma concentration (Cmax) and systemic exposure (AUC) by 100% and prolonged the time to reach peak plasma concentration (Tmax) by 2.5 hours.', 'high-fat foods', 'Major', 'Pexidartinib should be administered on an empty stomach, at least one hour before or two hours after a meal or snack.  Consumption of grapefruit or grapefruit juice should generally be avoided during pexidartinib therapy.  If concomitant use is unavoidable, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations.  If concomitant use of grapefruit or grapefruit juice is discontinued, the dose of pexidartinib may be increased (after 3 plasma half-lives of a strong CYP450 3A4 inhibitor) to the dose that was used prior to consumption of grapefruit or grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1776, 0, 'Pexidartinib', 'The presence of food may increase the absorption and toxicity of pexidartinib.  Administration of pexidartinib with a high-fat meal increased peak plasma concentration (Cmax) and systemic exposure (AUC) by 100% and prolonged the time to reach peak plasma concentration (Tmax) by 2.5 hours.', 'grapefruit juice', 'Major', 'Pexidartinib should be administered on an empty stomach, at least one hour before or two hours after a meal or snack.  Consumption of grapefruit or grapefruit juice should generally be avoided during pexidartinib therapy.  If concomitant use is unavoidable, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations.  If concomitant use of grapefruit or grapefruit juice is discontinued, the dose of pexidartinib may be increased (after 3 plasma half-lives of a strong CYP450 3A4 inhibitor) to the dose that was used prior to consumption of grapefruit or grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1777, 3826, 'Phenobarbital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1778, 0, 'Phenelzine', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1779, 24890, 'Phenylbutyric acid', 'Coadministration with a high-fat meal may reduce the rate and extent of absorption of sodium phenylbutyrate.', 'high-fat foods', 'Moderate', 'The prescribing information recommends administration of sodium phenylbutyrate-taurursodiol before a meal or snack, particularly in patients of low body weight (less than 70 kg).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1780, 0, 'Phenoxybenzamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1781, 26249, 'Phentolamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1782, 26250, 'Phentolamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1783, 0, 'Phentermine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1784, 0, 'Phendimetrazine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1785, 2177, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1786, 5954, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1787, 18352, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1788, 18425, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1789, 20272, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1790, 20929, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1791, 20930, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1792, 20931, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1793, 24859, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1794, 24872, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1795, 24875, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1796, 24876, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1797, 24877, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1798, 24878, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1799, 24879, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1800, 24880, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1801, 24881, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1802, 24882, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1803, 33404, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1804, 20843, 'Axitinib', 'Grapefruit juice may increase the plasma concentrations of axitinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with axitinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Axitinib may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1805, 20844, 'Axitinib', 'Grapefruit juice may increase the plasma concentrations of axitinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with axitinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Axitinib may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1806, 0, 'Pindolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1807, 24220, 'Pimozide', 'Theoretically, the coadministration with grapefruit juice may increase the plasma concentrations of pimozide.  The mechanism is decreased clearance of pimozide due to inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'The manufacturer recommends avoiding grapefruit juice (and probably grapefruits) during therapy with pimozide.  Patients should also be advised to avoid or limit consumption of alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1808, 24939, 'Pimozide', 'Theoretically, the coadministration with grapefruit juice may increase the plasma concentrations of pimozide.  The mechanism is decreased clearance of pimozide due to inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'The manufacturer recommends avoiding grapefruit juice (and probably grapefruits) during therapy with pimozide.  Patients should also be advised to avoid or limit consumption of alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1809, 24220, 'Pimozide', 'Theoretically, the coadministration with grapefruit juice may increase the plasma concentrations of pimozide.  The mechanism is decreased clearance of pimozide due to inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'alcohol', 'Major', 'The manufacturer recommends avoiding grapefruit juice (and probably grapefruits) during therapy with pimozide.  Patients should also be advised to avoid or limit consumption of alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1810, 24939, 'Pimozide', 'Theoretically, the coadministration with grapefruit juice may increase the plasma concentrations of pimozide.  The mechanism is decreased clearance of pimozide due to inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'alcohol', 'Major', 'The manufacturer recommends avoiding grapefruit juice (and probably grapefruits) during therapy with pimozide.  Patients should also be advised to avoid or limit consumption of alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1811, 121, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1812, 122, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1813, 3571, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1814, 3572, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1815, 3573, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1816, 3577, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1817, 4200, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1818, 4201, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1819, 6147, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1820, 6148, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1821, 13442, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1822, 13443, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1823, 19862, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1824, 19952, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1825, 19953, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1826, 19954, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1827, 19956, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1828, 24947, 'Pioglitazone', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1829, 1707, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1830, 3746, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1831, 3747, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1832, 3748, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1833, 3750, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1834, 3751, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1835, 4757, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1836, 4760, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1837, 4762, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1838, 4764, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1839, 4765, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1840, 4766, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1841, 4767, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1842, 4768, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1843, 6193, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1844, 6475, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1845, 6477, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1846, 15475, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1847, 17722, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1848, 18895, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1849, 18896, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1850, 18898, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1851, 18899, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1852, 20819, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1853, 20820, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1854, 20821, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1855, 20823, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1856, 20825, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1857, 24959, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1858, 24960, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1859, 24961, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1860, 24962, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1861, 24963, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1862, 29093, 'Piroxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1863, 2934, 'Pirfenidone', 'Food significantly slows the rate but only modestly reduces the extent of absorption of pirfenidone.  In healthy, older adult volunteers aged 50 to 66 years, administration of a single 801 mg oral dose of pirfenidone in the fed state resulted in an approximately 50% reduction in peak plasma concentration (Cmax) and a 15% to 20% reduction in systemic exposure (AUC) compared to administration in the fasted state.  Median time to reach peak concentration (Tmax) increased from 0.5 hours to 3 hours with food.  Less nausea and dizziness were observed in fed subjects compared to fasted subjects.', 'grapefruit juice', 'Moderate', 'Pirfenidone should be administered with food to reduce the likelihood of dizziness and gastrointestinal side effects such as nausea, diarrhea, dyspepsia, and vomiting.  Patients who experience intolerance to therapy due to these adverse events should be reminded to take pirfenidone with food.  If symptoms do not improve, or they worsen in severity, a dosage reduction or discontinuation of therapy may be warranted.  Patients should be advised to avoid consumption of grapefruit and grapefruit juice during treatment with pirfenidone.  Cigarette smoking should also be avoided during therapy to prevent reduced exposure to pirfenidone.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1864, 7009, 'Pirfenidone', 'Food significantly slows the rate but only modestly reduces the extent of absorption of pirfenidone.  In healthy, older adult volunteers aged 50 to 66 years, administration of a single 801 mg oral dose of pirfenidone in the fed state resulted in an approximately 50% reduction in peak plasma concentration (Cmax) and a 15% to 20% reduction in systemic exposure (AUC) compared to administration in the fasted state.  Median time to reach peak concentration (Tmax) increased from 0.5 hours to 3 hours with food.  Less nausea and dizziness were observed in fed subjects compared to fasted subjects.', 'grapefruit juice', 'Moderate', 'Pirfenidone should be administered with food to reduce the likelihood of dizziness and gastrointestinal side effects such as nausea, diarrhea, dyspepsia, and vomiting.  Patients who experience intolerance to therapy due to these adverse events should be reminded to take pirfenidone with food.  If symptoms do not improve, or they worsen in severity, a dosage reduction or discontinuation of therapy may be warranted.  Patients should be advised to avoid consumption of grapefruit and grapefruit juice during treatment with pirfenidone.  Cigarette smoking should also be avoided during therapy to prevent reduced exposure to pirfenidone.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1865, 24956, 'Pirfenidone', 'Food significantly slows the rate but only modestly reduces the extent of absorption of pirfenidone.  In healthy, older adult volunteers aged 50 to 66 years, administration of a single 801 mg oral dose of pirfenidone in the fed state resulted in an approximately 50% reduction in peak plasma concentration (Cmax) and a 15% to 20% reduction in systemic exposure (AUC) compared to administration in the fasted state.  Median time to reach peak concentration (Tmax) increased from 0.5 hours to 3 hours with food.  Less nausea and dizziness were observed in fed subjects compared to fasted subjects.', 'grapefruit juice', 'Moderate', 'Pirfenidone should be administered with food to reduce the likelihood of dizziness and gastrointestinal side effects such as nausea, diarrhea, dyspepsia, and vomiting.  Patients who experience intolerance to therapy due to these adverse events should be reminded to take pirfenidone with food.  If symptoms do not improve, or they worsen in severity, a dosage reduction or discontinuation of therapy may be warranted.  Patients should be advised to avoid consumption of grapefruit and grapefruit juice during treatment with pirfenidone.  Cigarette smoking should also be avoided during therapy to prevent reduced exposure to pirfenidone.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1866, 0, 'Pomalidomide', 'Cigarette smoking may reduce pomalidomide exposure due to induction of CYP450 1A2, the isoenzyme that is responsible for the metabolic clearance of pomalidomide along with CYP450 3A4.', 'cigarette', 'Moderate', 'Patients should be advised that smoking may reduce the efficacy of pomalidomide therapy.  Pomalidomide should be taken on an empty stomach, at least 2 hours before or 2 hours after a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1867, 224, 'Plantago seed', 'Bulk-forming laxatives such as guar gum, psyllium, polycarbophil, or methylcellulose may affect the bioavailability of concomitantly administered substances due to their effect on the rate of gastrointestinal transit and gastric emptying.', 'food', 'Moderate', 'In general, oral medications should be administered at least 2 hours before or 2 hours after dosing of the bulk-forming laxative.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1868, 21113, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1869, 21114, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1870, 21115, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1871, 21871, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1872, 21872, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1873, 21873, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1874, 21917, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1875, 21918, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1876, 21961, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1877, 24964, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1878, 24966, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1879, 24968, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1880, 33109, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1881, 33110, 'Pitavastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1882, 0, 'Ponatinib', 'Coadministration with grapefruit juice is likely to increase the plasma concentrations of ponatinib, which is primarily metabolized by CYP450 3A4.  However, the interaction has not been studied.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit extract should be avoided during treatment with ponatinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1883, 23820, 'Posaconazole', 'Food significantly increases the absorption of posaconazole from the oral suspension but only modestly from the delayed-release tablet.  Following single-dose administration, posaconazole mean peak plasma concentration (Cmax) and systemic exposure (AUC) are approximately 2.5 to 3 times higher when the oral suspension is given with a nonfat meal or a nutritional supplement (14 grams of fat) than when given under fasting conditions, and approximately 3.5 to 4 times higher when given during or 20 minutes after a high-fat meal (50 grams of fat) than under fasting conditions.  Acidic beverages may also increase posaconazole absorption.', 'high-fat foods', 'Moderate', 'Posaconazole tablets should be taken with food, whereas posaconazole oral suspension should be administered during or immediately (i.e., within 20 minutes) following a full meal to enhance bioavailability.  Patients who cannot eat a full meal should take the suspension with a liquid nutritional supplement or an acidic carbonated beverage such as ginger ale.  In patients who cannot eat a full meal or tolerate an oral nutritional supplement or an acidic carbonated beverage and who do not have the option of taking another formulation of posaconazole, alternative antifungal therapy should be considered; otherwise, monitor patients closely for breakthrough fungal infections.  Patients receiving posaconazole via a nasogastric tube should also be closely monitored due to increased risk of treatment failure associated with lower plasma exposure.  Administration of alcohol with posaconazole from the delayed-release oral suspension formulation is not recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1884, 23820, 'Posaconazole', 'Food significantly increases the absorption of posaconazole from the oral suspension but only modestly from the delayed-release tablet.  Following single-dose administration, posaconazole mean peak plasma concentration (Cmax) and systemic exposure (AUC) are approximately 2.5 to 3 times higher when the oral suspension is given with a nonfat meal or a nutritional supplement (14 grams of fat) than when given under fasting conditions, and approximately 3.5 to 4 times higher when given during or 20 minutes after a high-fat meal (50 grams of fat) than under fasting conditions.  Acidic beverages may also increase posaconazole absorption.', 'cola', 'Moderate', 'Posaconazole tablets should be taken with food, whereas posaconazole oral suspension should be administered during or immediately (i.e., within 20 minutes) following a full meal to enhance bioavailability.  Patients who cannot eat a full meal should take the suspension with a liquid nutritional supplement or an acidic carbonated beverage such as ginger ale.  In patients who cannot eat a full meal or tolerate an oral nutritional supplement or an acidic carbonated beverage and who do not have the option of taking another formulation of posaconazole, alternative antifungal therapy should be considered; otherwise, monitor patients closely for breakthrough fungal infections.  Patients receiving posaconazole via a nasogastric tube should also be closely monitored due to increased risk of treatment failure associated with lower plasma exposure.  Administration of alcohol with posaconazole from the delayed-release oral suspension formulation is not recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1885, 0, 'Pralsetinib', 'Food significantly increases the oral bioavailability of pralsetinib.  According to the product labeling, administration of pralsetinib with a high-fat meal (approximately 800 to 1000 calories; 50% to 60% from fat) increased mean pralsetinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 104% and 122%, respectively.  The median time to maximum concentration (Tmax) was delayed from 4 to 8.5 hours.', 'high-fat foods', 'Major', 'Pralsetinib should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.  Patients should avoid consumption of high-fat foods during treatment with pralsetinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1886, 0, 'Pralsetinib', 'Grapefruit juice may increase the plasma concentrations of pralsetinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to pralsetinib may increase the risk of adverse effects such as musculoskeletal toxicity, fatigue, constipation, hypertension, and pneumonia.', 'grapefruit juice', 'Major', 'Pralsetinib should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.  Patients should avoid consumption of grapefruit or grapefruit juice during treatment with pralsetinib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1887, 13086, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1888, 17831, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1889, 17832, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1890, 21425, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1891, 25669, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1892, 26928, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1893, 26929, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1894, 27124, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1895, 27125, 'Pramipexole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1896, 7403, 'Pravastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1897, 7405, 'Pravastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1898, 16265, 'Pravastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1899, 21898, 'Pravastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1900, 0, 'Pramlintide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1901, 1510, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1902, 15194, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1903, 15198, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1904, 17726, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1905, 18443, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1906, 25135, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1907, 25136, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1908, 25137, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1909, 26607, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1910, 1510, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1911, 15194, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1912, 15198, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1913, 17726, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1914, 18443, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1915, 25135, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1916, 25136, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1917, 25137, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1918, 26607, 'Praziquantel', 'Administration with food increases the oral bioavailability of praziquantel.  The mechanism has not been described.  In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions.', 'grapefruit juice', 'Moderate', 'To ensure maximal oral absorption, praziquantel should be administered with meals.  Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1919, 23305, 'Procarbazine', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1920, 0, 'Primidone', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1921, 0, 'Pretomanid', 'Food enhances the oral bioavailability of pretomanid.  The mechanism has not been reported.  Compared with the fasted state, oral administration of pretomanid with a high-fat, high-calorie meal (approximately 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) increased mean systemic exposure (AUC) and peak plasma concentration (Cmax) of pretomanid by 88% and 76%, respectively.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, pretomanid should be administered with food.  Tablets should be swallowed whole.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1922, 8197, 'Prazosin', 'The concurrent use of ethanol and alpha-1 adrenergic blockers may cause increased hypotensive effects.  Patients with aldehyde dehydrogenase deficiencies (primarily Asians) may be at a higher risk of this interaction.', 'alcohol', 'Moderate', 'Patients who develop  a flushing reaction after ethanol ingestion (indicates a possible aldehyde dehydrogenase deficiency) should be advised to avoid ethanol or limit their intake.  All patients should be warned about the possibility of orthostatic hypotension with concurrent ethanol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1923, 22784, 'Prazosin', 'The concurrent use of ethanol and alpha-1 adrenergic blockers may cause increased hypotensive effects.  Patients with aldehyde dehydrogenase deficiencies (primarily Asians) may be at a higher risk of this interaction.', 'alcohol', 'Moderate', 'Patients who develop  a flushing reaction after ethanol ingestion (indicates a possible aldehyde dehydrogenase deficiency) should be advised to avoid ethanol or limit their intake.  All patients should be warned about the possibility of orthostatic hypotension with concurrent ethanol use.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1924, 0, 'Procainamide', 'Ethanol may increase the acetylation of procainamide.  Subtherapeutic plasma levels of procainamide may result in some patients.  Because the acetylated metabolite of procainamide also possesses antiarrhythmic properties, the clinical effects are unclear.', 'alcohol', 'Minor', 'To ensure the therapeutic effect of Procainamide, we do not recommend that patients consume alcohol while on the medication.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1925, 1160, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1926, 1161, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1927, 3180, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1928, 5282, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1929, 5586, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1930, 6080, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1931, 6575, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1932, 6577, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1933, 6819, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1934, 6821, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1935, 6824, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1936, 7625, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1937, 7628, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1938, 7633, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1939, 10352, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1940, 13189, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1941, 14739, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1942, 14888, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1943, 16781, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1944, 17266, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1945, 17267, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1946, 17268, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1947, 17269, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1948, 17270, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1949, 19333, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1950, 19539, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1951, 19556, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1952, 19871, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1953, 19872, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1954, 20442, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1955, 21299, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1956, 21301, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1957, 21303, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1958, 21305, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1959, 21982, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1960, 21983, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1961, 22139, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1962, 22143, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1963, 22145, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1964, 22146, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1965, 22147, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1966, 22148, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1967, 22150, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1968, 22154, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1969, 23147, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1970, 23148, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1971, 23429, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1972, 23431, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1973, 23432, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1974, 23434, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1975, 23446, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1976, 23447, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1977, 23448, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1978, 23736, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1979, 23737, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1980, 24038, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1981, 24455, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1982, 24456, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1983, 24457, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1984, 24458, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1985, 25156, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1986, 25157, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1987, 25158, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1988, 25159, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1989, 25160, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1990, 25161, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1991, 25162, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1992, 25163, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1993, 25164, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1994, 25165, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1995, 25166, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1996, 25167, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1997, 25168, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1998, 25169, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1999, 25170, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (2000, 25171, 'Pregabalin', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);